Epithelium Another field of research has indicated that PKC-α plays a vital role in
epithelial tissue, the tissue that covers all external and internal surfaces of the body. Specifically, PKC-α is involved in altering the function of
tight junctions. Tight junctions exist at the meeting point between two cells. Here, tight junctions fuse together to form an impermeable barrier to not only large molecules such as proteins, but also smaller molecules like water. This prevents foreign molecules from entering the cell and helps regulate the internal environment of the cell. Cells infected with certain types of epithelial cancer exhibit increased PKC-α activity. This is a result of a change in the shape of the cell membrane, particularly in the areas where tight junctions exists. With greater activity of PKC-α, the tight junctions lose their ability to form a tight barrier. This causes an increased leakiness of the tight junctions and thus movement of molecules into the cells. In
intestinal areas,
luminal growth factors are able to enter the cell and increase the rate of cell growth. This is thought to be a promotional event that may prolong certain epithelial cancers.
Liver Much of the research of PKC alpha pertaining to its role in liver tissue involves the effects of bile acids on the phosphorylation mechanism of the PKC family of proteins. Past research has affirmed that the bile acid CDCA inhibits the healthy glucagon response through a phosphorylation-related sequence. In related studies further testing the effects of CDCA on hepatocytes, CDCA was shown to have induced PKC translocation to the plasma membrane. PKC alpha was favored in this process over PKC delta. The implications of this finding are that increased interaction between the glucagon receptor and PKC alpha could occur.
Heart PKC alpha is one of the lesser studied proteins of the PKC family because it is not highly regulated in the serious medical condition known as acute myocardial
ischemia, which results from a lack of blood supply to the
myocardium (heart muscle tissue). Recent research into the role of PKC alpha in cardiac tissue has indicated that it has an important role in stimulating
hypertrophy. This was demonstrated by the ability of agonist-mediated
hypertrophy to be stopped only as a result of the inhibition of PKC alpha in an experiment in situ. However, in further
in vivo research using mice, the
transgenic overexpression of PKC alpha showed no effect on cardiac growth, and the inhibition of PKC alpha showed no effect on
hypertrophic response to increased cardiac pressure. On the contrary, research has shown that removing PKC alpha altogether improved the hearts ability to contract. In summary, research is pointing in the direction that PKC alpha's role in cardiac tissue has more impact as a regulator of contractility than of
hypertrophy. In another study, the binding peptides, RACK and others derived from PKC beta, were expressed in mouse hearts. The genetic code for these
proteins are similar to those of all
isoforms of the PKC family (alpha, beta, and gamma). As such, RACK and other
proteins can regulate the expression of all PKC family proteins. In this particular study, however, only PKC alpha was affected. Again, overexpression caused decreased contractile performance, whereas inhibition saw increased performance.
Cell membrane PKC-α shows important regulation of
phospholipase D. Phospholipase D is located on the plasma membrane and is responsible for hydrolyzing phosphatidylcholine to phosphatidic acid and
choline. Research has indicated that phospholipase D may play roles in
tumorigenesis by altering cellular events such as invasion and migration. Point mutations at particular
phenylalanine residues have shown to inhibit PKC-α's ability to activate phospholipase D. Current research is being conducted investigating PKC-α's inhibitory affects. Researchers hope to learn how to exploit PKC-α's ability to turn down phospholipase D's activity and use this function to create anti-cancer drugs. Another breakthrough branch of research concerning PKC-α concerns its role in erythrocyte (red blood cell) development. Currently, researchers understand that PKC-α is correlated with the differentiation of erythroid progenitor cells in bone marrow. These undifferentiated cells give rise to the mass of red blood cells present in blood. Future research endeavors seek to find whether it is activation or inhibition of PKC-α which affects the development of erythrocytes. By answering this question, scientists hope to gain insight into various types of hematologic diseases such as aplastic anemia and leukemia. == Pathology ==